Related Experiment Video
Updated: Jan 17, 2026
Single-cell Analysis of Immunophenotype and Cytokine Production in Peripheral Whole Blood via Mass Cytometry
Published on: June 26, 2018
Targeting BCMA in CIDP: Valuable insights gained through multi-omics immune monitoring
Maximilian A Funk1, Sebastian Theurich1
1Department of Medicine III and Comprehensive Cancer Center (CCC Munich LMU), LMU University Hospital Munich, Munich, Germany; Cancer and Immunometabolism Research Group, Gene Center, Ludwig Maximilians University (LMU) Munich, Munich, Germany; German Cancer Consortium (DKTK), partner site Munich, a partnership between the DKFZ Heidelberg and the University Hospital of the LMU, Munich, Germany.
Abstract:
Dong et al. present two patients with refractory chronic inflammatory demyelinating polyneuropathy (CIDP), who received treatment with B-cell-maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR)-T cells.1 Extensive concomitant immune monitoring provides insights into the pathogenesis and mechanisms of relapse in CIDP that may help to determine the role of BCMA-targeted CAR-T cell therapy for this disease in the future.
